Dermatology
Dapsone
Brand: Dapsomed®
PBAC's latest decision on Dapsone: Recommended (2025). Considered for Dermatitis herpetiformis, leprosy, and actinomycotic mycetoma.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2025 → 2025
Eligible population
Patients with dermatitis herpetiformis, leprosy, or actinomycotic mycetoma requiring dapsone therapy, with 50 mg being the TGA-approved starting dose.
- Therapy area
- Dermatology
- Line of therapy
- Not applicable
- Evidence base
- Cost-minimisation
- Primary endpoint
- Cost-minimisation
- Comparator
- dapsone 25 mg tablet (DAPSONE)
- Economic model
- Cost-minimisation
- Budget impact
- $10M
- ICER note
- Cost-minimisation analysis; no ICER calculated as the submission compared bioequivalent formulations on a cost basis only.
Similar precedents
Open on full dashboard →